Professional
Added to YB: 2024-10-23
Pitch date: 2024-09-30
NVO [bullish]
Novo Nordisk A/S
-56.91%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 116.46
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
growth
Baron International Growth Fund Portfolio Holding: Novo Nordisk A/S
NVO: Leader in GLP-1 drugs for diabetes/obesity. Ozempic/Wegovy drive 15% weight loss, improve cardiovascular outcomes. Monlunabant setback irrelevant to thesis. Bullish on CagriSema (Ozempic + amylin agonist) and amycretin (dual GLP1/amylin agonist) as best-in-class GLP-1 drugs.
Read full article (1 min)